One Stop Solution For In-Depth Market Research Reports


Home    >    HEALTHCARE AND PHARMACEUTICALS   >   Non-Invasive Prenatal Testing Market

[ 英語タイトル ] Non-Invasive Prenatal Testing Market - Growth, Trends, and Forecasts (2020 - 2025)

Product Code : MDHC0084126
Survey : Mordor Intelligence
Publish On : November, 2020
Category : Healthcare and Pharmaceuticals
Study Area : Global
Report format : PDF
Sales price option (consumption tax not included)
Single User USD4250 / Question Form
5 User USD4750 / Question Form
Enterprise User USD7500 / Question Form
 - BGI
- Eurofins Scientific
- F. Hoffmann-La Roche Ltd (Roche Sequencing)
- Invitae Corporation
- Illumina, Inc.
- Natera, Inc.
- Progenity, Inc.
- PerkinElmer Inc.
- Quest Diagnostics

[Report Description]

Non-invasive prenatal testing market is primarily driven by the rising prevalence of genetic disorders, quick adoption on next-generation sequencing, new product launches, and an upsurge in several non-invasive prenatal testing service providers. For instance, in August 2019, Axia Women's Health, the nation's largest independent women's healthcare group announces the launch of non-invasive prenatal testing (NIPT), the first of its kind in a U.S. OB/GYN physician-owned laboratory.

Additionally, advantages of non-invasive prenatal tests over other prenatal tests such as non-invasive nature, better accuracy, and short duration of the procedure are anticipated to hasten the growth of the global non-invasive prenatal testing market during the forecast period. However, the lack of accessibility of test in emerging countries, ethical concerns, and strict government regulations are the few factors that will hamper the growth in the global Non-Invasive prenatal testing market.

Key Market Trends

Down Syndrome Segment Dominates the Non-Invasive Prenatal Testing Market

Down syndrome is a chromosomal disorder and also called trisomy 21, trisomy G, 47, XX,+21 and 47, XY,+21. It includes certain birth defects, learning problems, and facial features. A child with Down syndrome may also have heart defects and problems with vision and hearing. According to the Centers for Disease Control and Prevention 2019, down syndrome is the most common chromosomal condition diagnosed in the United States. Every year, about 6,000 babies born in the United States have Down syndrome. This means that Down syndrome occurs in about 1 out of every 700 babies.

The non-invasive prenatal test is a novel and sensitive screening for the diagnosis of Down syndrome. The test is done after 10 weeks and is more than 99% accurate for Down syndrome. This test is most suitable for women who are at increased risk of having a baby with Down syndrome.

North America Dominates the Global Non-Invasive Prenatal Testing Market

North America holds a leading position in the Non-Invasive Prenatal Testing market during the forecast period. Favorable reimbursement policies and an increase in the prevalence of genetic disorders will increase the adoption and demand for tests in this region.

According to Trisomy 18 Foundation, Edwards syndrome (Trisomy 18) error occurs in about 1 out of every 2500 pregnancies in the United States and 1 in 6000 live births. North America accommodates several major companies working on fetal and neonatal care from around the world, with direct distribution channels and third-party services for distribution in relation to medical/hospitals requirement. Furthermore, High rate of diagnosis, high adoption, and awareness among the people and the introduction of new and technologically advanced tests are also contributing to the growth of market in North America.

Competitive Landscape

Non-Invasive Prenatal Testing market is very competitive with most of the players competing to maximize market shares. Strong competition, rapid technological advancements, recurrent changes in government policies, and the prices are key factors that confront the market. Several biotechnology companies are now indulging in the research and development of such NGS-based NIPT products. Key market players in the market are BGI, CENTOGENE AG, Eurofins Scientific, F. Hoffmann-La Roche Ltd (Roche Sequencing), Invitae Corporation, Illumina, Inc., Natera, Inc., Progenity, Inc., PerkinElmer Inc., Quest Diagnostics.

Reasons to Purchase this report:

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

1.1 Study Assumptions and Market Definition
1.2 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Number of Babies with Chromosomal Disorders owing to Increasing Number of Late Pregnancies
4.2.2 Increasing Demand for Early and Non-invasive Fetal Diagnosis
4.2.3 Favorable Reimbursement Policies
4.3 Market Restraints
4.3.1 Lack of Skilled Professionals
4.3.2 Stringent Regulations and Ethical Concerns
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Component
5.1.1 Instruments
5.1.2 Kits and Reagents
5.1.3 Services
5.2 Application
5.2.1 Down syndrome (trisomy 21)
5.2.2 Edwards syndrome (trisomy 18)
5.2.3 Patau syndrome (trisomy 13)
5.2.4 Turner syndrome
5.2.5 Others
5.3 End User
5.3.1 Hospitals
5.3.2 Diagnostic Labs
5.4 Geography
5.4.1 North America United States Canada Mexico
5.4.2 Europe Germany United kingdom France Italy Spain Rest of Europe
5.4.3 Asia Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.4.4 Middle East and Africa GCC South Africa Rest of Middle East and Africa
5.4.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 BGI
6.1.3 Eurofins Scientific
6.1.4 F. Hoffmann-La Roche Ltd (Roche Sequencing)
6.1.5 Invitae Corporation
6.1.6 Illumina, Inc.
6.1.7 Natera, Inc.
6.1.8 Progenity, Inc.
6.1.9 PerkinElmer Inc.
6.1.10 Quest Diagnostics




Recommended reports